Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The Novavax Covid-19 vaccine, which goes by the Scrabble-friendly trade name “Nuvaxovid,” has been authorized as a two-dose primary series given three weeks. or roughly only two Scaramuccis apart.

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

The Novavax vaccine targets the same XBB.1.5 variant as the other two vaccines. That variant was the dominant one in the U.S. earlier this year when the FDA had to choose the makeup of this fall's ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

The Novavax vaccine would be authorized for use in adults only in two doses. The company submitted a request, which the FDA is considering, to provide the same vaccine as a booster dose.

Novavax COVID vaccine shows strong efficacy The biotechnology company announced Monday that its stage three clinical trial showed overall efficacy of 90.4% against COVID-19.

The Novavax vaccine was one of the vaccines chosen for development as part of Operation Warp Speed. The U.S. government is providing $1.75 billion to the company to support the vaccine's development.

In this Feb. 26, 2022 file photo a kidney dish with syringes containing the Novavax COVID-19 vaccine sits in a refrigerator ready for use at a vaccination center in Prisdorf, Germany, Feb. 26, 2022.

Novavax has been working on developing vaccines for more than three decades, but hasn’t brought one to market. The company’s COVID-19 vaccine work is partly funded by the U.S. government.

Novavax, a small biotech company in Maryland, garnered attention June 18 when it announced its vaccine candidate is more than 90% effective overall and 100% effective at preventing moderate to ...